Maureen A Mealy1, Sharon L Kozachik2, Michael Levy3. 1. Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, Maryland; Johns Hopkins University, School of Nursing, Baltimore, Maryland. Electronic address: mmealy1@jhmi.edu. 2. Johns Hopkins University, School of Nursing, Baltimore, Maryland. 3. Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Abstract
OBJECTIVES: Neuromyelitis optica spectrum disorder (NMOSD) causes disabling and persistent central neuropathic pain (NP). Because the pain syndrome in NMOSD is severe and often intractable to analgesic treatment, it interferes with quality of life in patients. No interventional trials have been published looking at response to interventions for pain in NMOSD. This is a synthesis of the literature surveying the impact on quality of life of interventions in all mechanisms of central spinal NP. This review has important implications for management of pain in NMOSD. METHODS AND DATA SOURCES: A systematic database search was conducted using PubMed, Embase, and CINAHL Plus with keywords including "spinal cord," "quality of life," and "neuropathic pain" in an attempt to identify original research that targeted spinal NP treatment and used quality of life as an outcome measure. Both pharmacologic and nonpharmacologic treatments were sought out. RESULTS: Twenty-one studies meeting our eligibility criteria were identified and evaluated, 13 using pharmacologic treatments and 8 using nonpharmacologic interventions. Overall, sample sizes were modest, and effects on decreasing pain and/or improving quality of life were suboptimal. CONCLUSIONS: This review provides researchers with a foundation from which to start a more thorough and thoughtful investigation into the management of NP in NMOSD and underscores the importance of including quality of life as a clinically meaningful outcome measure.
OBJECTIVES:Neuromyelitis optica spectrum disorder (NMOSD) causes disabling and persistent central neuropathic pain (NP). Because the pain syndrome in NMOSD is severe and often intractable to analgesic treatment, it interferes with quality of life in patients. No interventional trials have been published looking at response to interventions for pain in NMOSD. This is a synthesis of the literature surveying the impact on quality of life of interventions in all mechanisms of central spinal NP. This review has important implications for management of pain in NMOSD. METHODS AND DATA SOURCES: A systematic database search was conducted using PubMed, Embase, and CINAHL Plus with keywords including "spinal cord," "quality of life," and "neuropathic pain" in an attempt to identify original research that targeted spinal NP treatment and used quality of life as an outcome measure. Both pharmacologic and nonpharmacologic treatments were sought out. RESULTS: Twenty-one studies meeting our eligibility criteria were identified and evaluated, 13 using pharmacologic treatments and 8 using nonpharmacologic interventions. Overall, sample sizes were modest, and effects on decreasing pain and/or improving quality of life were suboptimal. CONCLUSIONS: This review provides researchers with a foundation from which to start a more thorough and thoughtful investigation into the management of NP in NMOSD and underscores the importance of including quality of life as a clinically meaningful outcome measure.
Authors: J H Vranken; M W Hollmann; M H van der Vegt; M R Kruis; M Heesen; K Vos; A J Pijl; M G W Dijkgraaf Journal: Pain Date: 2011-02 Impact factor: 6.961
Authors: Matagne Heutink; Marcel W M Post; Helma M H Bongers-Janssen; Catja A Dijkstra; Govert J Snoek; Dorien C M Spijkerman; Eline Lindeman Journal: Pain Date: 2011-11-17 Impact factor: 6.961
Authors: Susanna Asseyer; Felix Schmidt; Claudia Chien; Michael Scheel; Klemens Ruprecht; Judith Bellmann-Strobl; Alexander U Brandt; Friedemann Paul Journal: Mult Scler J Exp Transl Clin Date: 2018-08-30
Authors: Andrea Salazar-Camelo; Naveen George; Hesham Abboud; Sarah M Planchon; Marcelo Matiello; Maureen A Mealy; Andrew Goodman Journal: J Neurol Date: 2021-09-05 Impact factor: 4.849